Journal: Human Molecular Genetics

Article Title: ROM1 contributes to phenotypic heterogeneity in PRPH2-associated retinal disease

doi: 10.1093/hmg/ddaa160

Figure Lengend Snippet: Antibodies used. Antibodies used are listed here. WB: western blot, IF: immunofluorescence

Article Snippet: Available from Millipore Cat# MABN1757 M-Opsin Rabbit Opsin 1 (Medium Wave) 1:1000 (IF) Novus Biologicals cat# 110–74 730 RRID:AB_1049390 S-Opsin Rabbit 1:1000 (IF) Novus Cat# NBP1–20194, RRID:AB_2299094 Rhodopsin Mouse 1D4 1:2000 (IF) Gift from R. Molday Can be purchased: Santa Cruz Biotechnology Cat# sc-57 432, RRID:AB_785511 Actin-HRP Mouse AC-15 1:50 000 (WB) Sigma-Aldrich Cat# A3854, RRID:AB_262011 Rabbit IgG HRP Goat 1:25 000 (WB) SeraCare KPL Cat# 074–1506, RRID:AB_2721169 Mouse IgG HRP Goat 1:25 000 (WB) Millipore Cat# AP130P, RRID:AB_91266 Rabbit IgG Alexa Flour 488 Donkey 1:1000 (IF) Thermo Fisher Scientific Cat# A-21206, RRID:AB_2535792 Mouse IgG Alexa Fluor 555 Donkey 1:1000 (IF) Thermo Fisher Scientific Cat# A-31570, RRID:AB_2536180 Open in a separate window Antibodies used.

Techniques: Western Blot

Journal: Journal of Biological Chemistry

Article Title: Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity

doi: 10.1074/jbc.m110.115790

Figure Lengend Snippet: FIGURE 2. Effect of XOMA 052 on IL-1 binding to receptors. XOMA 052 reduces the affinity of IL-1 binding to sRI measured by KinExA from 2 to 10 nM (n 5) (a) but has no effect on the affinity of IL-1 binding to sRII of 2 nM (n 2) (b). XOMA 052 reduces the affinity of sRAcP binding to sRIIL-1 complex from 25 (c) to 69 nM (d), as measured by SPR. XOMA 052 shifts the apparent affinity of Alexa Fluor 647-labeled IL-1 binding to HEK293 cells expressing IL-1RI and IL-1RAcP from 2 to 9 nM (n 2) (e).

Article Snippet: Recombinant human IL-1Ra (catalog number 280-RA), sRI (catalog number 269-1R-100/CF), sRII (catalog number 263-2R-050/CF), and sRAcP Fc chimera (catalog number 676-CP-100) were purchased from R&D Systems.

Techniques: Binding Assay, Labeling, Expressing

Journal: Experimental and Therapeutic Medicine

Article Title: Salidroside protects against intestinal barrier dysfunction in septic mice by regulating IL‑17 to block the NF‑κB and p38 MAPK signaling pathways

doi: 10.3892/etm.2023.11788

Figure Lengend Snippet: Salidroside affects the ileum tissue injury and intestinal permeability induced by a septic model and regulates ileum tissue cytokines. (A) The ileum tissues of mice were examined by histopathological examination. (B) FD4 concentration was measured by fluorospectrophotometer to detect intestinal permeability. (C-F) The cytokine levels of (C) IL-17, (D) IL-6, (E) IL-13 and (F) TNF-α in ileum were detected by ELISA. The data are presented as the mean ± standard deviation of three independent experiments; *** P<0.001 vs. sham; # P<0.05; ## P<0.01; ### P<0.001 vs. model; ^ P<0.05; ^^^ P<0.001 vs. salidroside (320 mg/kg). FD4, fluorescein isothiocyanate-dextran.

Article Snippet: Salidroside (CAS: 10338-51-9; cat. no. SMB00072; purity ≥95%) was purchased from MilliporeSigma.

Techniques: Permeability, Concentration Assay, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Experimental and Therapeutic Medicine

Article Title: Salidroside protects against intestinal barrier dysfunction in septic mice by regulating IL‑17 to block the NF‑κB and p38 MAPK signaling pathways

doi: 10.3892/etm.2023.11788

Figure Lengend Snippet: Salidroside attenuates the decrease in the levels of intestinal tight junction proteins in a septic model. (A) The levels of intestinal tight junction proteins (B) ZO-1, (C) occludin and (D) claudin-5 were detected by western blotting. GAPDH was served as the internal reference. The data are presented as the mean ± standard deviation of three independent experiments. *** P<0.001 vs. sham; ## P<0.01 vs. model; ^ P<0.05; ^^ P<0.01 vs. salidroside (320 mg/kg). ZO-1, zonula occludens-1.

Article Snippet: Salidroside (CAS: 10338-51-9; cat. no. SMB00072; purity ≥95%) was purchased from MilliporeSigma.

Techniques: Western Blot, Standard Deviation

Journal: Experimental and Therapeutic Medicine

Article Title: Salidroside protects against intestinal barrier dysfunction in septic mice by regulating IL‑17 to block the NF‑κB and p38 MAPK signaling pathways

doi: 10.3892/etm.2023.11788

Figure Lengend Snippet: Salidroside affects the activation of NF-κB and p38 MAPK pathways in a septic model. (A) The NF-κB and (B) p38 MAPK signaling pathways activation was detected by ELISA. (C) Western blotting was performed to determine the protein expressions of (D) NF-κB p65 and (E) p38 MAPK. GAPDH was served as the internal reference. The data are presented as the mean ± standard deviation of three independent experiments; *** P<0.001 vs. sham; # P<0.05; ## P<0.01; ### P<0.001 vs. model; ^^ P<0.01; ^^^ P<0.001 vs. salidroside (320 mg/kg).

Article Snippet: Salidroside (CAS: 10338-51-9; cat. no. SMB00072; purity ≥95%) was purchased from MilliporeSigma.

Techniques: Activation Assay, Protein-Protein interactions, Enzyme-linked Immunosorbent Assay, Western Blot, Standard Deviation

Journal: Experimental and Therapeutic Medicine

Article Title: Salidroside protects against intestinal barrier dysfunction in septic mice by regulating IL‑17 to block the NF‑κB and p38 MAPK signaling pathways

doi: 10.3892/etm.2023.11788

Figure Lengend Snippet: Anti-IL-17A further affects the ileum tissue injury and intestinal permeability and regulated ileum tissue cytokines in sepsis mice treated with salidroside. (A) The ileum tissues of mice were examined by histopathological examination. (B) FD4 concentration was measured by fluorospectrophotometer to detect intestinal permeability. (C) IL-17, (D) IL-6, (E) IL-13 and (F) TNF-α levels in ileum were detected by ELISA. The data are presented as the mean ± standard deviation of three independent experiments; *** P<0.001 vs. sham; ## P<0.01; ### P<0.001 vs. model; ^ P<0.05; ^^ P<0.01; ^^^ P<0.001 vs. model + salidroside (160 mg/kg); § P<0.05; §§ P<0.01 vs. model + anti-IL-17A. FD4, fluorescein isothiocyanate-dextran.

Article Snippet: Salidroside (CAS: 10338-51-9; cat. no. SMB00072; purity ≥95%) was purchased from MilliporeSigma.

Techniques: Permeability, Concentration Assay, Enzyme-linked Immunosorbent Assay, Standard Deviation

Journal: Experimental and Therapeutic Medicine

Article Title: Salidroside protects against intestinal barrier dysfunction in septic mice by regulating IL‑17 to block the NF‑κB and p38 MAPK signaling pathways

doi: 10.3892/etm.2023.11788

Figure Lengend Snippet: Anti-IL-17A further attenuates the decreases in the levels of intestinal tight junction proteins in sepsis mice treated with salidroside. (A-D) The levels of intestinal tight junction proteins (B) ZO-1, (C) occludin and (D) claudin-5 were detected by western blotting. GAPDH was served as the internal reference. The data are presented as the mean ± standard deviation of three independent experiments; *** P<0.001 vs. sham; ## P<0.01; ### P<0.001 vs. model; ^ P<0.05; ^^ P<0.01 vs. model + salidroside (160 mg/kg); § P<0.05 vs. model + anti-IL-17A. ZO-1, zonula occludens-1.

Article Snippet: Salidroside (CAS: 10338-51-9; cat. no. SMB00072; purity ≥95%) was purchased from MilliporeSigma.

Techniques: Western Blot, Standard Deviation

Journal: Experimental and Therapeutic Medicine

Article Title: Salidroside protects against intestinal barrier dysfunction in septic mice by regulating IL‑17 to block the NF‑κB and p38 MAPK signaling pathways

doi: 10.3892/etm.2023.11788

Figure Lengend Snippet: Anti-IL-17A further affects the activated NF-κB and p38 MAPK pathways in sepsis mice treated with salidroside. The activation of (A) NF-κB and (B) p38 MAPK signaling pathways was examined by ELISA. (C) Western blotting was performed to detect the (D) p-NF-κB p65/NF-κB p65 and (E) -p38 MAPK/p38 MAPK protein expressions and GAPDH was served as the internal reference. The data were presented as the mean ± standard deviation of three independent experiments; *** P<0.001 vs. sham; ## P<0.01 vs. model; ^ P<0.05; ^^ P<0.01 vs. salidroside (160 mg/kg), ^^^ P<0.001; § P<0.05; §§ P<0.01 vs. model + anti-IL-17A, §§§ P<0.001..

Article Snippet: Salidroside (CAS: 10338-51-9; cat. no. SMB00072; purity ≥95%) was purchased from MilliporeSigma.

Techniques: Activation Assay, Protein-Protein interactions, Enzyme-linked Immunosorbent Assay, Western Blot, Standard Deviation